Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon Jan 27, 2024 8:07pm
138 Views
Post# 35848939

RE:RE:Does CG0070 have better efficacy than Ruvidar PDT?

RE:RE:Does CG0070 have better efficacy than Ruvidar PDT?

Yes great comparison and I would also like to see how our durable CR rate improves with some patients getting a 3rd treatment.  


digitalstone wrote:

Eoganacht wrote: It's too early to tell as CG Oncology has not revealed 9, 12, and 15 month data. It looks close. They definitely require a lot more treatments to get this result.

  3 mths 6 mths 9 mths 12 mths 15 mths
CG0070
standalone
phase 3
68.20% 63.60% ? ? ?
Ruvidar PDT
optimized
62% 60% 45% 40% 39%


 

Thanks Eoganacht for sharing this great comparison. 


 

<< Previous
Bullboard Posts
Next >>